Advanced drug delivery of n-acetylcarnosine (n-acetyl-beta-alanyl-l-histidine), carcinine (beta-alanylhistamine) and l-carnosine (beta-alanyl-l-histidine) in targeting peptide compounds as pharmacological chaperones for use in tissue engineering, human disease management and therapy: From in vitro to the clinic

Recent Patents on Drug Delivery and Formulation

Volumn 4, Issue 3, 2010, Pages 198-230

  Babizhayev, Mark A ^a,b   Yegorov, Yegor E ^c  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Age related cataract; Age related macular degeneration; Carcinine; Chemical and pharmacological chaperones; Cosmetic science; Diabetic retinopathy; Formulations and products; Human cataractous lenses; L carnosine; Lipid hydroperoxides; Lipid peroxidation; N acetylcarnosine; Natural imidazole containing peptidomimetics; Non enzymatic glycation; Ocular complications of diabetes; Ophthalmic treatment; Oxidative stress; Photoaging; Protein cross linking; Review of patent protection; Skin care; Sod like activity; Transglycation activity; Universal antioxidants

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA CRYSTALLIN; BETA CRYSTALLIN; BOVINE SERUM ALBUMIN; CAN C; CARCININE; CHAPERONE; CLARASTILL; COLLAGEN; CRYSTALLIN; ELASTIN; EYE DROPS; FREE RADICAL; GAMMA CRYSTALLIN; HEAT SHOCK PROTEIN; HISTAMINE H3 RECEPTOR ANTAGONIST; HYDROPEROXIDE; LENS CRYSTALLIN; LEVO CARNOSINE; LINOLEIC ACID HYDROPEROXIDE; LIPID PEROXIDASE; LIPOSOME; MALONALDEHYDE; MEMBRANE LIPID; METHYLGLYOXAL; N ACETYLCARNOSINE; PEPTIDOMIMETIC AGENT; POLAPREZINC; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TROLOX LEVO CARNOSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ANTIOXIDANT ACTIVITY; ARTICLE; BLINDNESS; CATARACT; CATARACTOGENESIS; COLITIS; COLON MUCOSA; DERMIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PURITY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENTHALPY; ENTROPY; EPIDERMIS; HUMAN; LENS; LIPID PEROXIDATION; METAL BINDING; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN TERTIARY STRUCTURE; RETINA MACULA AGE RELATED DEGENERATION; SEBACEOUS GLAND; SKIN CAPILLARY; SKIN FUNCTION; SKIN STRUCTURE; STOMACH MUCOSA; SUBCUTANEOUS TISSUE; ULTRAVIOLET IRRADIATION; WRINKLE;

ANIMALS; CARNOSINE; DRUG DELIVERY SYSTEMS; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; PATENTS AS TOPIC; PROTEIN FOLDING; TISSUE ENGINEERING;

EID: 78650009053     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221110793237547     Document Type: Article

References (452)

1. Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell 2006; 5:125(3): 443-451.
2. Ellis RJ, van der Vies SM. Molecular chaperones. Annu Rev Biochem 1991; 60: 321-347.
3. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996; 13: 381(6583): 571-579.
4. Macario AJ, Conway de ME. Sick chaperones, cellular stress, and disease. N Engl J Med 2005; 353:1489-1501.
5. Chaudhuri TK, Paul S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 2006; 273(7):1331-1349.
6. Gething MJ, Sambrook J. Protein folding in the cell. Nature 1992; 2: 355(6355): 33-45.
7. Fenton WA, Horwich AL. GroEL-mediated protein folding. Protein Sci 1997; 6(4):743-760.
8. Zhang C, Kim SH. Overview of structural genomics: From structure to function. Curr Opin Chem Biol 2003; 7(1): 28-32.
9. Babizhayev MA. Biological activities of the natural imidazole-containing peptidomimetics N-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci 2006; 78(20): 2343-2357.
10. Severin SE. Problems concerned with the biological activity of naturally occurring imidazole compounds. Proc Plen Sess 7th Int Biochemic Cong NY 1964; 45-61.
11. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: Distribution, properties and biological significance. Adv Enzyme Regul 1990; 30: 175-194.
12. Yan H, Harding JJ. Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochim Biophys Acta 2005; 1741(1-2):120-126.
13. Babizhayev MA, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J Drug Target 2009; 17(1): 36-63.
14. Babizhayev MA, Deyev AI, Yermakova VN, Yu SA, Davydova NG, Kurysheva NI, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22: 979-994.
15. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R & D 2002; 3(2): 87-103.
16. Babizhayev MA, Deyev AI, Yermakova VN, Remenschikov VV, Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther 2006; 1: 91-116.
17. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R & D 2004; 5(3): 125-139.
18. Babizhayev, M.A. Method for topical treatment of eye disease and composition and device for said treatment. WO2004028536 (2004).
19. Babizhayev MA. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol 2006; 1(3): 201-233.
20. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res 2004; 7:186-198.
21. Babizhayev MA, Yermakova VN, Deyev AI, Seguin M.-C. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti-Aging Med 2000; 3: 43-62.
22. Krantz S, Lober M, Henschel L. The nonenzymatic glycation of proteins and nucleic acids, their importance for the development of diabetic complications, possible molecular basis of aging and autoimmunological processes. Exp Clin Endocrinol 1986; 88(3): 257-269.
23. Luthra M, Balasubramanian D. Nonenzymatic glycation alters protein structure and stability. A study of two eye lens crystallins. J Biol Chem 1993; 25: 268(24):18119-18127.
24. Baynes JW, Watkins NG, Fisher CI, Hull CJ, Patrick JS, Ahmed MU, et al. In: Baynes JW, Monnier VM, Eds. The Maillard reaction in Aging, Diabetes, and Nutrition Alan R. Liss, Inc., New York 1989; 85-107.
25. Njoroge FG, Monnier VM. In The Maillard reaction in Aging, Diabetes, and Nutrition (Baynes J W, Monnier VM, eds) Alan RL, Inc., New York 1989; 85-107,.
26. Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM. Aging of proteins: Immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. J Biol Chem 1989; 5: 264(7): 3758-3764.
27. McPherson JD, Shilton BH, Walton DJ. Role of fructose in glycation and cross-linking of proteins. Biochemistry 1988; 27(6):1901-1907.
28. Suárez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose. J Biol Chem 1989; 264(7): 3674-3679.
29. Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem 199; 266(12): 7329-7332.
30. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 1992; 267(15):10211-10214.
31. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267(8): 5133-5138.
32. Harding JJ, Dilley KJ. Structural proteins of the mammalian lens: A review with emphasis on changes in development, aging and cataract. Exp Eye Res 1976; 22(1):1-73.
33. Kohn RR, Monnier VM. Clinical Pharmacology in the Elderly5133-5138 In: Swift CG, ed. USA, New York, Marcel Dekker, Inc. 1987; 3-30.
34. Cerami A, Vlassara H, Brownlee M. Role of nonenzymatic glycosylation in atherogenesis. J Cell Biochem 1986; 30(2): 111-120.
35. Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, Cerami A. Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages. A model for turnover of aging cells. J Exp Med 1987; 166(2): 539-549.
36. Monnier VM, Stevens VJ, Cerami A. Nonenzymatic glycosylation, sulfhydryl oxidation, and aggregation of lens proteins in experimental sugar cataracts. J Exp Med 1979; 150(5): 1098-1107.
37. Hamlin CR, Kohn RR, Luschin JH. Apparent accelerated aging of human collagen in diabetes mellitus. Diabetes 1975; 24(10): 902-904.
38. Pongor S, Ulrich PC, Bencsath FA, Cerami A. Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA 1984; 81(9): 2684-2688.
39. Schnider SL, Kohn RR. Effects of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen. J Clin Invest 1981; 67(6):1630-1635.
40. Monnier VM, Sell DR, Abdul-Karim FW, Emancipator SN. Collagen browning and cross-linking are increased in chronic experimental hyperglycemia. Relevance to diabetes and aging. Diabetes 1988; 37(7): 867-872.
41. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232(4758):1629-1632.
42. Rahbar, S., Figarola, J.L. Methods of lowering lipid levels in a mammal. US7652037 (2010).
43. Baker, J.R., Cooper, G.J.S. Treatment of diabetes with copper binding compounds. US7459446 (2008).
44. Hongjian, Y., Dailin, L. Application of procyanidin B2 in preparing medicine for preventing and treating diabetes and vascular complication. CN11125139A (2008).
45. Jonas, M., Vaulont, I., Soi, A., Schmidt, G. Synthesis of triethylenetetramines. US7582796 (2009).
46. Trouba KJ, Hamadeh HK, Amin RP, Germolec DR. Oxidative stress and its role in skin disease. Antioxid Redox Signal 2002; 4(4): 665-673.
47. Schmenger, J., Braun, P., Kujawa, J., Glattefelder, M., Entzminger, A., Sallwey, A., Deutz, H. Agent for coloring keratin fibres. US7648535 (2010).
48. Schmenger, J., Braun, P. Multicomponent kit and method for dyeing keratin fibers. US7637962 (2009).
49. Sunkara, H.B. Personal care compositions. US7628999 (2009).
50. Tonkovich, A.L., Silva, L.J., Hesse, D.J., Marchiando, M.A., Lamont, M.J., Qiu, D., Dritz, T.A., Pagnotto, K.M., Stevenson, R., Perry, S.T., Fanelli, M., Arora, R., Yang, B., Fitzgerald, S.P., Sullivan, T.J., Jarosch, K.T.P., Yuschak, T. Multiphase mixing process using microchannel process technology. US7622509 (2009).
51. Cannell, D.W., Van Nguyen, N. Methods for relaxing and re-waving hair comprising at least one reducing agent and at least one hydroxide compound. US7622104 (2009).
52. Malik, S. Wound and skin care compositions. US7608642 (2009).
53. Viaud, G., Budris, K., Canfield, D., Dasilva, D., Dornbusch, J., Robinson, J. Programmable, multi-spectral, image-capture environment. US7603031 (2009).
54. Birkel, S., Wendel, H., Franzke, M., Hannich, M. Aerosol foam or pump foam product for hair treatment. US7597898 (2009).
55. Schmenger, J., Kujawa, J., Bonn, M. Dyes for keratinic fibers comprising a special anionic thickener. US7591862 (2009).
56. Commo, S., Gaillard, O., Bernard, B. Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes. US7585514 (2009).
57. Yoneda, T. Method for stabilizing oil-based thickening gel composition.US7569231 (2009).
58. Martin, K.M., Saliou, C. Composition containing feverfew extract and use thereof. US7547456 (2009).
59. Hunter, I.W. Measuring properties of an anatomical body. US7530975 (2009).
60. Day, A.G., Estell, D.A., Murray, C.J., Power, S.D. Peptides and supported peptides for treating skin diseases. US7524816 (2009).
61. Snow, A.D., Nguyen, B.P., Castillo, G.M., Sanders, V.J., Lake, T.P., Larsen, L., Weavers, R.T., Lorimer, S.D., Larsen, D.S. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease. US7514583 (2009).
62. Cavazzuti, R., Ferrari, V., Mattox, B., Pinzon, CO., Thau, P. At least one polyamide polymer in a cosmetic composition comprising at least one solid substance having a melting point of 45°C or greater. US7491749 (2009).
63. Qiu, D., Tonkovich, A.L., Silva, L., Long, R.Q., Yang, B.L., Trenkamp, K. M. Process for forming an emulsion using microchannel process technology. US7485671(2009).
64. Day, A.G., Murray, C.J., Power, S.D., Rider Turnquest, B. FGF-5 supported and binding peptides. US7485618 (2009).
65. Estell, D.A., Ganshaw, G.C., Harding, F.A., Larenas, E.A., Poulose, A.J., Sikorski, E.E., Russell, E.P. Proteins producing an altered immunogenic response and methods of making and using the same. US7476528 (2009).
66. Van Nguyen, N., Cannell, D.W. Compositions comprising at least one hydroxide compound and at least one oxidizing agent, and methods to straighten curly hair. US7468180 (2009).
67. Schmenger, J., Braun, P., Englisch, W. Dye-containing pellets for dyeing keratin fibres. US7458992(2009).
68. Baumoeller, G., Kawa, R., Spoerer, R., Eichhorn, S. Emulsions made from particular emulsifers. US7452917 (2008).
69. Angel, A.B., Hunter, I.W. Needleless injector. US7425204 (2008).
70. Malik, S. Skin care products. US7419655 (2008).
71. Jianguo, W., Chenqing, W. Scraping oil, preparation method and application thereof. CN11244235 (2008).
72. Jianguo, W., Chenqing, W. Composition for treating eye disease and preparation method. CN11244126 (2008).
73. Jianguo, W., Chenqing, W. Hair-nourishing and hair care combination and preparing method thereof. CN11244020A(2008).
74. Collin, N. Cosmetic composition comprising a polymer and fibres. US7410636 (2008).
75. Beltran, J.B.U., Bonaventura, J.S. Use of cationic preservative in food products. US7407679 (2008).
76. Seguer Bonaventura, J., Rocabayera, B. X. Enzymatic synthesis of N°-acyl-L-arginine esters. US7399616 (2008).
77. Wille, J.J. Anti-irritant. Botanicals. US7399493 (2008).
78. Hongfei, W., Qiang, L., Hong, L., Xubo, S., Bing, D., Dong, L. China skin-protecting and hair-protecting products containing Prinsepia utilis royle oil. CN11199461 (2008).
79. Natsch, A., Flachsmann, F. Compounds and use to reduce the formation of malodour. US7388105 (2008).
80. Callaghan, T., Oddos, T., Gendimenico, G., Martin, K. Topical composition comprising feverfew. US7387807 (2008).
81. Lin, C.B., Seiberg, M., Chen, N. Treatment of dry eye. US7381707 (2008).
82. Collin, N. Cosmetic composition comprising a polymer blend. US7351418 (2008).
83. Murray, M.A., Crawford, A.W., Fast, D.J., Dong, D., Huang, M., Connor, L.M. Plant based formulations for improving skin moisture, texture, and appeara. US7348034 (2008).
84. Estell, D.A., Harding, F.A. Protease producing an altered immunogenic response and methods of making and using the same. US7332320 (2008).
85. Santosa S, Jones PJ. Oxidative stress in ocular disease: Does lutein play a protective role? CMAJ 2005; 173(8): 861-862.
86. Benedini, F., Bonfanti, A. Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology. WO2010012567 (2010).
87. Hwang, S.-I. Pyrimidine-2, 4-diamine JAK2 kinase inhibiting anti-inflammation use. US20100029675 (2010).
88. Kis, G.L. Nutritional supplement composition for treatment of ocular diseases. US20100028459 (2010).
89. Klock, G., Freyberg, M.A., Kaiser, D. Anti-apoptotically active apatamers. US7655773 (2010).
90. Sah, D.W. Y., Johansen, T.E., Rossomando, A. Methods of activating RET receptor tyrosine kinase using neurotrophic factors. US7655463 (2010).
91. Tiltan Pharma Ltd. Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases. WO2010136396 (2010).
92. Ohashi, Y., Ohashi, K. Prophylactic or therapeutic agent for age-related macular degeneration. WO2010010939 (2010).
93. Umeda, N., Mochizuki, N., Uchida, S., Ikeyama, S. Diamine derivative, production process therefor and antioxidant. US7652155 (2010).
94. Cooke, J., Heeschen, C., Weis, M. Methods of reducing angiogenesis. US7652038 (2010).
95. Robinson, M.R., Blanda, W.M. Method for treating atrophic age related macular degeneration. WO2010009034 (2010).
96. Baron, D., Hirai, K. Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues. WO2010008746 (2010).
97. Robinson, M.R., Blanda, W.M., Hughes, P.M., Burke, J.A., Whitcup, S.M. Method for treating atrophic age related macular degeneration. US20100015158 (2010).
98. Pericak-Vance, M.A., Haines, J., Postel, E., Agarwal, A. Hauser, M.A., Schmidt, S., William, K. Genetic variants increase the risk of age-related macular degeneration. EP1861511 (2007).
99. Jerdan, J.A., Zilliox, P., Robertson, S.M. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration. EP1539182 (2005).
100. Spaide, R. Autofluorescence photography using a fundus camera. US7648239 (2010).
101. Research Development Foundation. RTEF-1 variants and the Use thereof for inhibition of angiogenesis. WO2010154351 (2010).
102. Fovea Pharmaceuticals. Compositions and methods for prophylaxis and treatment of cellular degenerative disorders. WO2010083188 & WO2010083185 (2010).
103. Campochiaro, P. A. Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa. WO2010005533 (2010).
104. Stout, T.J., Mcfarland, T. RTEF-1 variants and the use thereof for inhibition of angiogenesis. WO2008154351 (2008).
105. Morgan, B.P., Harris, C.L., Hakobyan, S. Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration. EP2109621 (2009) & US20100009393 (2010).
106. Reich, S.J., Surace, E.M., Tolentino, M.J. Compositions and methods for siRNA inhibition of HIF-1 alpha. US7645744, US20090191263 (2009) & US7645744 (2010).
107. Li, H., Lee, Y.-J. Treating retinal degeneration caused by retinal vein occlusion or retinal ischemia. US7645447 (2010).
108. Romano, C. Treatment of age-related macular degeneration using inhibitors of complement factor D. EP2139471 (2010).
109. Yokoyama, T., Inoue, T. Drug for preventing or treating angiogenic eye diseases. EP1614428 (2006).
110. Scott, I.L., Kuksa, V.A., Orme, M.W., Little, T., Gall, A., Hong, F. Alkoxy compounds for disease treatment. US20090326074 (2009).
111. Cooper, E.R., Kleinman, D.M., Nivaggioli, T., Dor, P.J.M., Mudumba, S. Transscleral delivery. US20090324686, US20090324687, US20090324688, US20090324689 & US20090324690 (2009).
112. Jablonski, M.M. Glycan-binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon. WO2008121768 (2008).
113. Durlach, J. Novel use of zinc N-acetyltaurinate. WO2009112758 (2009).
114. Hughes, A.E. Protection against and treatment of age related macular degeneration. US20090312394 (2009).
115. Wilkinson, B., Moss, S., Zhang, M. Novel compounds. US20090312316 (2009).
116. Khachik, F., Chang, A. -N. Process for synthesis of (3S)- and (3R)-3-hydroxy-beta-ionone, and their transformation to zeaxanthin and beta-cryptoxanthin. US20090311761 (2009).
117. Tao, S.L., Klassen, H.J., Young, M.J. Ocular scaffolds and methods for subretinal repair of bruch's membrane. US20090306772 (2009).
118. Caiado De, C.N.J., Stefani, M.A., Rossi, G., Mota, A.D., Alves, C. R., Cardillo, J.A., Kerr Azevedo, J. Method and system for control of therapeutic procedure.US20090306634 (2009).
119. Seddon, J.M., Daly, M. Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk. WO2009146204 (2009).
120. Mckay, B., Martens, J.A. Methods and compositions for treating and identifying compounds to treat age-related macular degeneration. WO2009129497 (2009).
121. Wong, V.G. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor. US7625582 (2009).
122. Canter, J. A., Pericak-Vance, M.A. Methods and compositions for diagnosis of age-related macular degeneration.WO2009105757 (2009).
123. Ashkenazi, A., Fong, S., Goddard, A., Gurney, A.L., Katschke Jr, K.J., Lookeren, M.V., Wood, W.I., Helmy, K.Y. Crig polypeptide for prevention and treatment of complement-associated disorders. SG0156649 (2009).
124. Auricchio, A., Hildinger, M., Surace, E.M. Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization. EP2123306 (2009).
125. Hageman, G.S., Allikmets, R.L., Dean, M.C., Gold, A.M. Protective complement proteins and age-related macular degeneration. EP1996214 (2008).
126. Swaminathan, S., Madavalappil, K.P. Isolation and purification of carotenoids from marigold flowers. US7622599 (2009).
127. Reich, S.J. Compositions and methods for siRNA inhibition of angiogenesis. WO2007146953 (2007).
128. Miller, J.W., Gragoudas, E.S., Renno, R.Z. Methods and compositions for treating conditions of the eye. US20090286743 (2009).
129. Bonnel, S., Sahel, J. Combination drugs comprising vegf inhibitor and serine proteases/thrombolytic compounds for treating neovascular disorders. US20090285826 (2009).
130. Gertner, M., Hansen, S.D. Orthovoltage radiotherapy. US7620147 (2009).
131. Messina, D.J., Mistry, S., Hong, K.L.S., Kramer, B.C., Romanko, M.J. Treatment of Parkinson's disease and related disorders using postpartum derived cells.US7618622 (2009).
132. Sawada, N., Osanai, M., Nishikiori, N. Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability. US20090281184 (2009).
133. Scott, I.L., Kuksa, V.A., Orme, M.W., Hong, F., Little Jr., T.L., Kubota, R. Amine derivative compounds for treating ophthalmic diseases and disorders. US20090281149 (2009).
134. Hoh, J. Genes associated with macular degeneration. US20090281030 (2009).
135. Caiado De, C.N.J., Stefani, M.A., Rossi, G., Mota, A.D., Alves Costa, R., Cardillo, J. A., Kerr Azevedo, J. Methods and systems of treating age-related macular degeneration. EP2114327 (2009).
136. Allikmets, R.L., Hageman, G.S., Dean, M.C., Gold, A.M. Variants in complement regulatory genes predict age-related macular degeneration. EP1989319 (2008).
137. Pepys, M.B. Treatment and prevention of tissue damage. US7615543 (2009).
138. Severns, M.L. Macular function tester. US7614746 (2009).
139. Seddon, J.M. Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk. WO2009134709 (2009).
140. Bille, J. Photodynamic therapy for treatng age-related macular degeneration. WO2007138490 (2007).
141. Yates, J.R.W. Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof. US20090269761 (2009).
142. Hageman, G.S. Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration. EP2046807 (2009).
143. Coffey, P., Da Cruz, L. Membrane. WO2009127809 (2009).
144. Khachik, F., Chang, A.-N. Process for synthesis of (3r,3'r,6'r)-lutein and its stereoisomers. US20090264681 (2009).
145. Shuler Jr., K.R., Postel, E.A., Caldwell, J., Schmidt, S., Hauser, M. Phenotype-genotype relationship in age-related macular degeneration. US20090263801 (2009).
146. Jang, Y.S. Nozzle capable of eliminating leavings on the nozzle tip for automatic packer. KR9010064 (2009).
147. Deangelis, M.M., Ji, F. Methods and compositions for the diagnosis and treatment of angiogenic disorders. WO2009126894 (2009).
148. Kliman, G.H. Drug delivery devices, kits and methods therefor. WO2009097468 (2009).
149. Ambati, J. Methods and animal model for analyzing age-related macular degeneration. US20090260091 (2009).
150. Hageman, G.S. Diagnosis and treatment of age-related macular degeneration. US20090258822 (2009).
151. Leveillard, T.S., Jose A.M.-S., Saddek Hicks, D. Disease-associated protein. JP2009232843 (2009).
152. Ludwig, K.G. Nutritional supplement composition for treatment of ocular diseases. CN11557807 (2009).
153. Moon, Y.-C., Cao, L., Tamilarasu, N., Qi, H., Choi, S., Lennox, W.J., Corson, D.T., Hwang, S. Carboline derivatives useful in the inhibition of angiogenesis. US7601840 (2009).
154. Rosenblum, M., Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis. US7601341 (2009).
155. Iwata, T., Matsuno, K. Composition, kit and method for detecting aging and disease associated with vascular disorder. WO2009123224 (2009).
156. Kumar-Singh, R., Cashman, S.M. A humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration. WO2009102488 (2009).
157. Oliner, J.D. Angiopoietin-2 specific binding agent. JP2009225799 (2009).
158. Cooke, J., Jang, J., Tsao, P., Heeschen, C. Nicotine in therapeutic angiogenesis and vasculogenesis. US7598275 (2009).
159. Brazzell, R.K., Lambrou, G.N., Latour, E., Ottiecz, A., Wood, J.M. Pharmaceutical use of COX-2-inhibitors in angiogenesis-mediated ocular disorders.US20090247638 (2009).
160. Mitchell, C., Laties, A. Method for treatment of macular degeneration. US20090247483 (2009).
161. Hageman, G.S. Therapeutic compositions for age-related macular degeneration. US20090247451 (2009).
162. Jayakrishna, A. Methods and animal model for analyzing age-related macular degeneration. US7595430 (2009).
163. Bikbov, M.M., Altynbaev, U.R., Surkova, V.K., Usubov, E.L.-O. Treatment method of age-related macular degeneration. RU2368359 (2009).
164. Alcouffe, C., Badorc, A., Bono, F., Bordes, M.-F. Novel imidazo[1,5-A]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same. NZ0561205 (2009).
165. Onda, T., Tajima, H., Kawashima, K., Okamoto, K., Yamamoto, M., Inaba, T., Takeno, Y. Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein. NZ0548949 (2009).
166. Chao, H.-M. Protection of ferulic acid and/or tetramethylpyrazine against retinal ischaemia, glaucoma and siderosis oculi. US20090239875 (2009).
167. Khachik, F. Process for synthesis of (3R,3'R)-zeaxanthin and (3R,3'S;meso)-zeaxanthin from (3R,3'R,6'R)-lutein via (3R)-3',4'-anhydrolutein. US20090238933 (2009).
168. Veen, D.R.H. Contact lens with multiple pinholes. GB2458495 (2009).
169. Toth, C.A., Stopa, M., Bower, B.A. Method and system of coregistrating optical coherence tomography (OCT) with other clinical tests. US7593559 (2009).
170. Grosskreutz, C.L. Methods and compositions for preserving the viability of photoreceptor cells. US7592330 (2009).
171. Owen, K., Koo, S.I., Gross, K.L. Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals. CA2402121 (2009).
172. Oligino, T., Hahn, C. Treatment for ocular-related disorders. WO2009114373 (2009).
173. Cuthbertson, A., Verdugo-gazdik, M.E. Optical Imaging. US20090232741 (2009).
174. Ashley, B., Louis, M.C., Jane, H.P., Gordon, P.J., Beng, K.G., Vijaya, K., Mariana, E.S. Method of treatment of age-related macular degeneration(amd). CN11534826 (2009).
175. Matier, W.L., Patil, G. Amelioration of vitrectomy-induced cataracts. US7589107 (2009).
176. Ma JZ, Zhang SX. Endogenous angiogenic inhibitors in diabetic retinopathy. Joyce Tombrain-Tink, Colin JB, Ed. Opthalmology Research Ocular Angiogenesis Diseases, Mechanisms, and Therapeutics. Humana Press: USA 2006; 2: 23-44.
177. Benedini, F., Bonfanti, A. Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology. WO2010012567 (2010).
178. Pintor, J.J.J., Crooke, A. SIRNA and shRNA for the production of drugs for high intraocular pressure. WO2010010208 (2010).
179. Jiménez, A.I., Sesto, Á., Gascón, I., Román, J.P., González De, B.G. Methods and compositions for the treatment of eye disorders with increased intraocular pressure. US20100022623 (2010).
180. Jagtap, P., Pham-Huu, D.-P. Indenoisoquinolinone analogs and methods of use thereof. US7652028 (2010).
181. Shichiri, M., Tanaka, Y. Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor.US20100004327 (2010).
182. De Boer, J.F., Tearney, G.J., Bouma, B.E. Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands. US7643152, US7643153 & US7630083 (2010).
183. Szilvássy, Z., Rabloczky, G., Rabloczky, A., Nagy, P.L. Synergistic pharmaceutical combination for the prevention or treatment of diabetes. US7635674 (2009).
184. Gamache, D.A., Bingaman, D.P., Yanni, J.M., Graff, G., Kapin, M.A. Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid. CA2417282 (2009).
185. Gant, T.G., Sarshar, S. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity. US20090312435 (2009).
186. Iino, Y., Ikenoue, T., Kondo, N., Matsueda, H., Hatanaka, T., Hirama, R., Masuzawa, Y., Ohta, F., Yamazaki, A., Niwa, S., Yamamoto, T. Lactam compounds and pharmaceutical use thereof.US7632830 (2009).
187. Gin, D., Wilmot, J. Cephalotaxus esters, methods of synthesis, and uses thereof. WO2009148654 (2009).
188. Lee, J.J., Lee, J.-H., Lee, K., Hong, Y.-S., Shanthaveerappa, B.K., Jin, Y., Kim, J.H., Jin, X. Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component. US20090306078 & WO2008004798 (2009).
189. Wong, V.G. Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor. US7625582 (2009).
190. Carney, D.H., Steer, R.C. Method of treating degenerative diseases. WO2009120300 (2009).
191. Shepard, A.R., Pang, I.-H. RNAi inhibition of CTGF for treatment of ocular disorders. US7622454 (2009).
192. Westergaard, M., Thrue, C.A., Rasmussen, F.W., Hansen, H.F. Potent LNA oligonucleotides for the inhibition of HIF-1a expression. US7589190 & US20090286859 (2009).
193. Cho, Y.-J., Ahn, B.-Y., Kwon, O.-W., Kim, S.-J., Hong, S.-P., Yoo, W.-D., Kim, S.-O. Method for diagnosing diabetic retinopathy by single nucleotide polymorphism, DNA fragment thereof, and primer thereof. US20090286233 (2009).
194. De Gasparo, M., Webb, R.L. Method of treatment and pharmaceutical composition. CA2336822 (2009).
195. Huth, A., Zorn, L., Kruger, M., Ince, S., Thierauch, K.-H., Menrad, A., Haberey, M., Hess-Stumpp, H. VEGFR-2 and VEGRF-3 inhibitory anthranilamide pyridines. US7615565 (2009).
196. Brown, T.R., Keppler, F. Methods for alleviating deleterious effects of 3-deoxyglucosone. US7615528 (2009).
197. Nicolaides, N.C., Grasso, L., Sass, P.M. Antibodies with immune effector activity and that internalize in endosialin-positive cells. US7615372 (2009).
198. Shitara, K., Ito, M., Hanai, N., Kawada, Y., Nakamura, K., Shibuya, M. Anti-human VEGF receptor FLT-1 monoclonal antibody. US7615214 & US7615215 (2009).
199. Mcnamara, T., Chandler, S.P. Ophthalmic NSAIDs as adjuvants. WO2009105534 (2009).
200. Miyata, J., Yokota, M., Naito, R., Kamikawa, A., Kawakami, M., Hattori, K. 2-Phenylthiophene derivative. US7612108 (2009).
201. Mascarenhas, D. Metal-binding therapeutic peptides. US7611893 (2009).
202. Hilberg, F., Solca, F., Stefanic, M.F., Baum, A., Munzert, G., Van Meel, J.C. A. Combinations of (Z)-3-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone. NZ0543774 (2009).
203. Kahn, D.A. Powell Ian Retinal fundus surveillance method and apparatus. WO2009129624 (2009).
204. Yu, D.M. VEGF receptor fusion protein and use thereof. EP2000483 (2008).
205. Xia, T., Long, S., Xining, G. Chinese medicament for treating diabetic retinopathy CN11564491 (2009).
206. Tsaj, T.P., Firoznia, F., Gerten, K.R., Tsi, L. Substituted 2-acyl-2-aminothiazoles. RU2371438 (2009).
207. Yu, M.D. VEGF receptor fusion proteins, their pharmaceutical compositions and therapeutic applications for the eye diseases. US20090264358 (2009).
208. Jang, Y.S. Nozzle capable of eliminating leavings on the nozzle tip for automatic packer. KR9010064 (2009).
209. Lee, C.W. Portable roaster having a table function. KR9010030 (2009).
210. Iino, Y., Ikenoue, T., Kondo, N., Matsueda, H., Hatanaka, T., Hirama, R., Masuzawa, Y., Ohta, F., Yamazaki, A. Lactam compounds and medical use thereof. EP1346993 (2009).
211. Noriyuki, S., Masakazu, M., Koya, K. Blood test device. CN11553725 (2009).
212. Brazzell, R. K., Lambrou, G.N., Latour, E., Ottiecz, A., Wood, J. M. Pharmaceutical use of COX-2-inhibitors in angiogenesis-mediated ocular disorders. US20090247638 (2009).
213. Dasseux, J.-L.H., Oniciu, C.D. Dihydroxyl compounds and compositions for cholesterol management and related uses. US20090247489 (2009).
214. Alcouffe, C., Badorc, A., Bono, F., Bordes, M.-F. Novel imidazo[1,5-A]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same. NZ0561205 (2009).
215. Honda, T., Tajima, H., Kawashima, K., Okamoto, K., Yamamoto, M., Inaba, T., Takeno, Y. Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein. NZ0548949 (2009).
216. Tran, T.-A., Chen, W. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto. WO2009117095 (2009).
217. Jiménez, A.I., Sesto, A., Gascón, I., Román, J.P., González De, B.G. Methods and compositions for the treatment of eye disorders with increased intraocular pressure. US7592325 (2009).
218. Oligino, T., Hahn, C. Treatment for ocular-related disorders.WO2009114373 (2009).
219. Durlach, J. Novel use of zinc N-acetyltaurinate. WO2009112758 (2009).
220. Jiansheng, G. Chinese-medicinal preparation for treating early diabetic retinopathy. CN10540022 (2009).
221. Gilbard, J.P. Seddon J.M. Dietary supplement for eye health. WO2009111603 & US20090226547 (2009).
222. Flugelman, M. Compositions and methods for treating ophthalmic disorders.WO2008152507 (2009).
223. Harats, D., Greenberger, S., Breitbart, E. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy. US7585666 (2009).
224. Cooper, E.R., Kleinman, D.M., Nivaggioli, T., Dor, P.J.M., Mudumba, S. Transscleral delivery. US7585517 (2009).
225. Fraley, M.E., Hartman, G.D., Hoffman, W.F., Hungate, R.W., Bilodeau, M.T., Kim, Y., Arrington, K.L. Indole derivatives as tyrosine kinase inhibitors. CA2387351 (2009).
226. Kireshita, S., Hirai, S., Ohashi, T., Sasaoka, M. Prophylactic or therapeutic agent for posterior eye disease containing quinazolinone derivative or quinoxaline derivative as active ingredient. JP2009196973 (2009).
227. Kamei, S., Tano, Y., Yamamoto, T., Nishida, K., Suzuki, M., Sakaguchi, H. Agent for inhibiting progress of or treating retinopathy caused by angiopathy. JP2009196927 (2009).
228. Bicknell, R., Huminiecki, L. Imaging, diagnosis and treatment of disease. US7582440 (2009).
229. Fung, S.C., Yao, Z. Use of complement inhibitors to treat ocular diseases. US20090214538 (2009).
230. Gavrilova, N., Saburina, I., Mironov, N. Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy. US20090214485 (2009).
231. Miyata, J., Naito, R., Kawakami, M., Asano, T. 2-Phenylpyridine derivative. EP1783116 (2009).
232. Rosen, C.A., Hu, J.-S., Cao, L. Antibodies to human vascular endothelial growth factor 2 and methods of using the same. US7576189 (2009).
233. Dasseux, J.-L.H., Oniciu, C. Dihydroxyl compounds and compositions for cholesterol management and related uses. US7576130 (2009).
234. Ferrara, N., Kuo, S.S. Polypeptides homologous to VEGF and BMP1. US7575879 (2009).
235. Shinohara, N., Mori, M., Kurokawa, K. Blood test device. EP2088425 (2009).
236. Mylari, B.L. Pyridazinone aldose reductase inhibitors. US7572910 (2009).
237. Gerritsen, M.E., Hongo, J.-A.S., Zlot, C.H. Methods and compositions for selective modulation of vascularization. US7572447 (2009).
238. Kubota, R., Fawzi, A., Scott, I.L., Kuksa, V.A. Compositions and methods for treatment of ophthalmic diseases and disorders. US20090197967 (2009).
239. Roth, G.J., Heckel, A., Lehmann-lintz, T., Kley, J., Hilberg, F., Van Meel, J.C.A., Tontsch-grunt, U. Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments. US20090197876 (2009).
240. Stefek, M., Snirc, V., Demopoulos, V.J., Djoubissie, P.-O., Rackova, L., Majekova, M., Karasu, C. Use of carboxymethylated pyridoindoles and pharmaceutical composition containing them. SK0286958 (2009).
241. Nishimura T., Iino T., Nagata Y., Eiki J. Novel aminobenzamide derivative. EP1496052 (2005).
242. Whitty, A., Runkel, L., Brickelmaier, M., Hochman, P. Fusion proteins of interferon beta-1a and use thereof. CZ0300762 (2009).
243. Yu, Q. Compositions of Angiopoietin, fragments, mutants and analogs thereof and uses of the same. US7569543 (2009).
244. Hulin, B., Piotrowski, D.W. Proline derivatives and their use as dipeptidyl peptidase IV inhibitors. NZ0550229 (2009).
245. Auricchio, A., Hildinger, M., Surace, E.M. Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization. US20090192115 (2009).
246. Kim, C.W., Yoo, H., Kim, J.-C., Kim, P.K., Park, H.W., Kim, MIR. Biomarker for diagnosis of diabetic retinopathy. JP2009168819 (2009).
247. Benedek GB. Cataract as a protein condensation disease: The proctor lecture. Invest Ophthalmol Vis Sci 1997; 38(10):1911-1921.
248. Goldstein, L.E., Chylack Jr., L.T., Bush, A.I. Methods for diagnosing a neurodegenerative condition. US7653428 (2010).
249. Motamedi, M.E., Dabiri, A. Method and apparatus for early diagnosis of Alzheimer's using non-invasive eye tomography by terahertz. US7641343 (2010).
250. Matier, W.L., Patil, G. Amelioration of vitrectomy-induced cataracts. US7589107 (2009).
251. Prokai, L., Prokai, K., Simpkins, J., Agarwal, N. Prodrugs for use as ophthalmic agents. US7572781 (2009).
252. Baogen, W., Zhigang, Z., Dan, W. Functional beverage containing xanthophyll microcapsule. CN11433357 (2009).
253. Prokai, L., Prokai, K. Quinol compound and pharmaceutical composition. US7534779 (2009).
254. Baogen, W., Zhigang, Z., Dan, W. Diet replenisher containing natural carotenol and its preparation technique. CN11283806 (2008).
255. Mcardle, G.J., Olejniczak, B.L., Kuszak, J.R. Apparatus and processes for preventing or delaying onset or progression of age-related cataract. US20080161781 (2008).
256. Hotamisligil, G.S., Ozcan, U., Manning, B.D. Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis. US20100022495 (2010).
257. Truog, P. Dosage forms having prolonged active ingredient release.US7611729 (2009).
258. Pregel, M.J., Hirth, B.H., Kane Jr., J.L., Qiao, S., Gregory, J., Cuff, L. Tetrahydroisoquinoline derivatives for treating protein trafficking diseases. US7541466 (2009).
259. Fan, J.-Q., Ishii, S. Method for enhancing mutant protein activity. US7514453 (2009).
260. Dunn-Coleman, N., Ward, M. BGL7 beta-glucosidase and nucleic acids encoding the same. US7407788 (2008).
261. Dunn-Coleman, N., Goedegebuur, F., Ward, M. BGL5 (3-glucosidase and nucleic acids encoding the same. US7045332 (2006), US7344871, US7320886, & US7005289 (2008).
262. Fischer, H., Illek, B. Compositions and methods for cystic fibrosis therapy. US7335683 (2008).
263. Umut, H.G.S.O. Reducing ER stress in the treatment of obesity and diabetes. CN11056656 (2007).
264. Teem, J.L. Materials and methods for detecting interaction of CFTR polypeptides. US7238474 (2007).
265. Schubert, U. Agents for the inhibition of virus replication through regulation of protein folding. US20070141074 (2007).
266. Hotamisligil, G.S., Ozcan, U. Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis.WO2007053747 (2007).
267. Fan, J.-Q., Ishii, S., Asano, N. Method for enhancing mutant enzyme activities in gaucher disease. US6916829 & US7141582 (2006).
268. Hotamisligil, G.S., Ozcan, U. Reducing ER stress in the treatment of obesity and diabetes. US20060073213 & WO06031931 (2006).
269. Winnacker, E.-L., Edenhofer, F., Rieger, R. Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPSc.US20050227287 (2005).
270. Schubert, U. Means for inhibiting viral replication by regulation of protein folding. WO2005063281 (2005).
271. Bai C, Biwersi J, Verkman AS, Matthay MA. A mouse model to test the in vivo efficacy of chemical chaperones. J Pharmacol Toxicol Methods 1998; 40: 39-45.
272. Perlmutter DH. Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 2002; 52: 832-836.
273. Welch WJ, Brown CR. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1996; 1: 109-115.
274. Diamant S, Eliahu N, Rosenthal D, Goloubinoff P. Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses. J Biol Chem 2001; 276: 39586-39591.
275. Papp E, Csermely P. Chemical chaperones: Mechanisms of action and potential use. Handb Exp Pharmacol 2006; 172 (451) [Document: 12 p.] (3 p. 1/2), pp. 405-416 [12 page(s) (article)] Springer, Berlin, ALLEMAGNE (1978) (Revue).
276. Meriin AB, Sherman MY. Role of molecular chaperones in neurodegenerative disorders. Int J Hyperthermia 2005; 21: 403-419.
277. Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA. The proteome of central and peripheral retina with progression of age-related macular degeneration. Invest Ophthalmol Vis Sci 2006; 47: 2280-2290.
278. Ma Y, Hendershot LM. ER chaperone functions during normal and stress conditions. J Chem Neuroanat 2004; 28: 51-65.
279. Tuo J, Bojanowski CM, Zhou M, Shen D, Ross RJ, Rosenberg KI, et al. Murine CCL2/CX3CR1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 3827-3836.
280. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature 2003; 426: 905-909.
281. Sauer T, Patel M, Chan CC, Tuo J. Unfolding the therapeutic potential of chemical chaperones for age-related macular degeneration. Expert Rev Ophthalmol 2008; 3(1): 29-42.
282. Bernier V, Lagace M, Bichet DG, Bouvier M. Pharmacological chaperones: Potential treatment for conformational diseases. Trends Endocrinol Metab 2004; 15: 222-228.
283. Pardo, G., Connors, K.S., Cunanan, C. Intraocular pressure attenuation device. WO2007121485 (2007).
284. Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones. WO2010134628 (2010).
285. Lockhart, D., Wustman, B. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological. WO2008134628 (2008).
286. Palling, D. Method for the treatment of fabry disease using pharmacological chaperones. EP2142197 & WO2008121826 (2010).
287. Lockhart, D. Treatment of Gaucher's disease with specific pharmacological chaperones and monitoring treatment using surrogate markers. EP2139323, WO2008128106, CA2683713 & AU8240138 (2010).
288. Benjamin, E., Do, H.V. Method to predict response to pharmacological chaperone treatment of diseases. WO2009102895 (2009).
289. Fan, J.-Q., Valenzano, K., Lee, G., Bouvier, M. Pharmacological chaperones for treating obesity. WO06133098, CA2610860, AU6255131 (2006), US20070021433 (2007), KR8034877, EP1885366 (2008), US20090312345 & WO06133098 (2009).
290. Fan, J.-Q., Ishii, S., Method of enhancing lysosomal a-galactosidase A.US7622485 (2009).
291. Brandon, W. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes. CN11541172 (2009).
292. Wustman, Br., Do, H. Assays for diagnosing and evaluating treatment options for pompe disease. WO2009114712 (2009).
293. Wustman, Br., Do, H. Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers. WO2009114679 (2009).
294. Jian-Qiang, F., Ken, V., Gary, L., Michel, B. Pharmacological chaperones for treating obesity. CN11535342& ZA0710981 (2009).
295. Mahuran, D.J., Tropak, M.B., Buttner, J.D., Blanchard, J.E., Brown, E.D. Method for treating Gaucher's disease. JP2009137933, WO2009038695 & US20090075960 (2009).
296. Mahuran, D.J., Tropak, M.B. Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and Parkinson's disease. WO2009049422 & WO2009049421 (2009).
297. Fan, J.-Q., Ishii, S. Method for enhancing mutant protein activity. US7514453 (2009).
298. Kato, M., Kikuchi, H., Kato, S. Cushion for polishing pad and polishing pad using the cushion. KR9021393 (2008).
299. Benjamin, M., Gary, L., Xiaoxiang, Z., Robert, B., Kamlesh, S. Method for the treatment of Pompe disease using 1- deoxynojirimycin and derivatives. CN11355971 (2009).
300. Pey, R.A., Martinez, R.A. Compositions for the treatment of hyperphenylalaninemia. WO2009000552 (2009).
301. Sanz, J.S., Casasin, N.C., Campoy, A.V., Ying, M., Pey, A.L., Martinez, A. Compositions for the treatment of hyperphenylalaninemia. EP2008656 (2008).
302. Wustman, B., Lockhart, D. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones. AU8245578 (2008).
303. Amicus Therapeutics Inc. Univ Montreal. Pharmacological chaperones for treating obesity. IL0187806 (2008).
304. Mugrage, B. Use of substrates as pharmacological chaperones. WO2008128089, CA2684042 & AU8240205 (2008).
305. Kopito, R.R., Zhang, W. Compositions and methods for high throughput screening of pharmacological chaperones. US20070270486 (2007) & EP1982189 (2008).
306. Palling, D. Method for the treatment of fabry disease using pharmacological chaperones. WO2008121826, CA2682441 & AU8232614 (2008).
307. Kaneski, C, Shin, S.-H., Murray, G., Ludwig, K., Lockhart, D., Castelli, J. Assays for diagnosing and evaluating treatment options for Fabry disease. US20080056994 (2008).
308. Lee, G., Fan, J.-Q., Vanlenzano, K., Bouvier, M. Pharmacological chaperones for treating obesity. MX2007015225 (2007).
309. Wustman, B. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes. MX2007015602 (2007).
310. Mugrage, B. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives. US20060264467 (2006), MX2007014470 & WO06125141 (2007).
311. Wustman, B.A. Method for the treatment of neurological disorders by enhancing the activity of p-glucocerebrosidase. CA2656643 (2007) & US20080009516 (2008).
312. Wustman, B. Method for the treatment of neurological disorders by enhancing the activity of ss-glucocerebrosidase. WO2007150064 (2007).
313. Fan, J.-Q., Ishii, S., Asano, N. Method for enhancing mutant enzyme activity in Gaucher disease. US6916829 (2005).
314. Simmen, K.A., De Kock, H.A., Raboisson, P.J.-M., Hu, L., Surleraux, D.L., Nilsson, K.M., Samuelsson, B.B., Rosenquist, A.A.K., Salvador Oden, L. Macrocylic inhibitors of hepatitis C virus. US20090062311 (2009).
315. Schilling, S., Niestroj, A.J., Heiser, U., Buchholz, M., Demuth, H.-U. Inhibitors of glutaminyl cyclase.US7371871 (2008).
316. Niestroj, A., Heiser, U., Demuth, H.-U. Inhibitors of dipeptidyl peptidase I. US7144856 (2006).
317. Salvati, M.E., Balog, J.A., Pickering, D.A., Giese, S., Fura, A., Li, W., Patel, R.N., Hanson, R.L., Mitt, T., Roberge, J.Y., Corte, J.R., Spergel, S.H., Rampulla, R.A., Misra, R.N., Xiao, H.-Y. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. US7517904 (2009) & US7655689 (2010).
318. Salvati, M.E., Attar, R.M., Gottardis, M.M., Balog, J.A., Pickering, D.A., Martinez, R.L., Sun, C. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function. US7655688 (2010).
319. Murali, R., Greene, M.I. Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same. US7653495 (2010).
320. Thurieau, C.A., Poitout, L.F., Galcera, M.-O., Gordon, T.D., Morgan, B.A., Moinet, C.P., Bigg, D.C.H.Imidazolyl derivatives. US7638546 & US7566734 (2009).
321. Cho, H.S., Daniel, T.O., Hays, A.-M., Wilson, T.E., Litzinger, D.C., Mariani, R., Kimmel, B.E., Keefe, W.M. Biosynthetic polypeptides utilizing non-naturally encoded amino acids. US7638299 (2009).
322. Cho, H.S., Daniel, T.O., Hays, A.-M., Wilson, T.E., Cujec, T.P., Tian, F., Hays, A.-M., Kimmel, B.E., Ho, L. Antigen-binding polypeptides and their uses. US7632924 (2009).
323. Zhu, Z., Mazzola, R., Guo, Z., Lavey, B.J., Sinning, L., Kozlowski, J., Mckittrick, B., Shih, N.-Y. Compounds for the treatment of inflammatory disorders. US7034057 (2006) & US7598242 (2009).
324. Saha, A.K., End, D.W., De Corte, B.L.D., Breslin, H.J., Liu, L. Triazoles as farnesyl transferase inhibitors. US7592356 (2009).
325. Sin, N., Scola, P.M., Meanwell, N.A., Wang, X.A., Sun, L.-Q., Chen, J., Good, A.C. Hepatitis C virus inhibitors. US7592336 (2009).
326. Collins, J.M., Lambert, J.J., Collins, M.J. Microwave-assisted peptide synthesis. US7563865, US7550560 & US7393920 (2009).
327. Glasky, A.J., Fick, D.B., Helton, D.R. Methods for treating ognitive/attention deficit disorders using tetrahydroindolone nalogues and derivatives. US6982269 (2006) & US7531670 2009).
328. Lin, J., Artis, D.R., Ibrahim, P.N., Zhang, C, Zuckerman, R., Bremer, R., Shi, S., Lee, B. PPAR active compounds. US7531568 2009).
329. Bhatia, P.A., Daanen, J.F., Hakeem, A.A., Kolasa, T., Matulenko, M.A., Mortell, K.H., Patel, M.V., Stewart, A.O., Wang, X., Xia, Z., Zhang, H.Q. Acetamides and benzamides that are useful in treating sexual dysfunction. US7528134 (2009).
330. Artis, D.R., Ibrahim, P.N., Lin, J., Zhang, C. PPAR active compounds. US7491831 (2007) & US7476746 (2009).
331. Che, C.-M., Wong, M.-K. Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrin catalysts. US7482478 (2009).
332. Suzuki, S., Shinoda, M., Kogushi, M., Kobayashi, H. Cyclic amidine derivatives. US7476688 (2009).
333. Degenhardt, C.R., Eickhoff, D.J. Substituted heterocyclic compounds for treating multidrug resistance.US7476680 (2009).
334. Schilling, S., Hoffmann, T., Niestroj, A.J., Demuth, H.-U., Heiser, U. Use of effectors of glutaminyl and glutamate cyclases. US7462599 (2008).
335. Braun, A., Cantor, C.R., Kammerer, S.M., Taylor, S., Burns-hamuro, L., Cook, C., Olson, G., Self, C. Kinase anchor protein muteins, peptides thereof and related documents. US7432342 (2008).
336. Demuth, H.-U., Hoffmann, T., Niestroj, A.J., Schilling, S., Heiser, U. Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease. US7381537 (2008).
337. Shimomura, N., Sasho, M., Kayano, A., Yoshizawa, K., Tsujii, M., Kuroda, H., Furukawa, K. Methods for producing cyclic benzamidine derivatives. US7375236 (2008).
338. Von Hoersten, S., Demuth, H.-U., Hoffmann, T. Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents. US7109347 (2006) & US7368576 (2008).
339. Arnold, J., Artis, D.R., Hurt, C.R., Ibrahim, P.N., Krupka, H., Lin, J., Milburn, M.V., Wang, W., Zhang, C. PPAR active compounds. US7202266 (2007) & US7348338 (2008).
340. Salvati, M.E., Balog, J.A. Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function. US7342034 (2008).
341. Demuth, H.-U., Hoffmann, T., Schlenzig, D., Heiser, U. Effectors of dipeptidyl peptidase IV for topical use. US7335645 (2008).
342. Suzuki, S., Kotake, M., Miyamoto, M., Kawahara, T., Kajiwara, A., Hishinuma, I., Okano, K., Miyazawa, S., Clark, R., Ozaki, F., Sato, N., Shinoda, M., Kamada, A., Tsukada, I., Matsuura, F., Naoe, Y., Terauchi, T., Oohashi, Y., Ito, O., Tanaka, H., Musha, T., Kogushi, M., Kawata, T., Matsuoka, T., Kobayashi, H., Chiba, K.-I., Kimura, A., Ono, N. 2-Iminoimidazole derivatives. US7244730 & US7304083 (2007).
343. Degenhardt, C.R., Eickhoff, D.J. Substituted heterocyclic compounds for treating multidrug resistance. US7135483 (2006) & US7304053 (2007).
344. Patel, S. SC6 for diagnosis of cancers. US7300765 (2007).
345. Salvati, M.E., Balog, J.A., Pickering, D.A., Zhu, H. Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function. US7291637 (2007).
346. Thurkauf, A., He, X.-S., Zhao, H. High affinity small molecule C5a receptor modulators. US7271270 (2007).
347. Kreutter, K., Lu, T., Lee, Y.K., Teleha, C., Player, M., Zhu, X. Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls. US7262210 (2007).
348. Portoghese, P.S., Jones, R.M., Sharma, S.K. Therapeutic compounds and methods. US7232829 (2007).
349. Nazare, M., Laux, V., Bauer, A., Wagner, M. Triazole-derivatives as blood clotting enzyme factor Xa inhibitors. US7223780 (2007).
350. Graupe, M., Palmer, J.T., Aldous, D.J., Thurairatnam, S. Compounds and compositions as cathepsin inhibitors. US7196099 (2007).
351. Van Heerden, F.R., Vleggaar, R., Horak, R.M., Learmonth, R.A., Maharaj, V., Whittal, R.D. Pharmaceutical compositions having appetite suppressant activity.US7166611 (2007).
352. Kronenthal, D.R., Bhandaru, R.S., Shi, Z., Mudryk, B.M. Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds. US7074921 (2006).
353. Graupe, M., Palmer, J.T., Patterson, J.W., Aldous, D.J., Thurairatnam, S., Timm, A.P., Link, J., Li, J. Compounds and compositions as cathepsin inhibitors.US7030116 (2006).
354. Hickey, E.R., Bekkali, Y., Patel, U.R., Spero, D.M., Thomson, D.S., Young, E.R.R. Nitriles useful as reversible inhibitors of cysteine proteases. US6982263 (2006).
355. Li, J., Aldous, D.J., Thurairatnam, S. Compounds and compositions as cathepsin S inhibitors. US6977256 (2005).
356. Thurkauf, A., He, X.-S., Zhao, H., Peterson, J., Zhang, X., Brodbeck, R., Krause, J., Maynard, G., Hutchison, A. High affinity small molecule C5a receptor modulators. US6884815 (2005).
357. Kitajima, N. Microscopic device for ophthalmic treatment. WO2009157222 (2009).
358. Gertner, M., Arnoldussen, M., Herron, M., Liang, J. Method and device for ocular alignment and coupling of ocular structures. WO2008150331 (2008) & US20090163898 (2009).
359. Kanngiesser, H. Protective foil for ophthalmic treatment. EP1891915 (2009).
360. Charles, S.T. Semi-automated ophthalmic photocoagulation method and apparatus. WO2009045286 & US20090093798 (2009).
361. Christian, J., Conston, S.R., Kupiecki, D.J., Mckenzie, J. Composite ophthalmic microcannula. SG0149883 (2009).
362. Beccaro, M., Bettini, E. Device for ophtalmic treatments and methods for making said device. WO2009016547 (2009).
363. Ebner, A., Galli, B. Pharmaceutical compositions comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer. US20080287417 (2008).
364. Okamoto, S. Tray for ocular instillation for displaying instillation schedule. JP2008272415 (2008).
365. Yuko, H., Hiroshi, K., Masayuki, M., Wataru, O. Ophthalmic treatment apparatus. CN10418496 (2008).
366. Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem J 1994; 304 (Pt 2): 509-516.
367. Arnould JM, Frentz R. Carcinine (p-alanyl-histamine): Rapid synthesis and action on vertebrate blood pressure. Arch Int Physiol Biochim 1977; 85(2): 339-350.
368. 2+ transport against damage induced by lipid peroxidation Biull Eksp Biol Med 1984; 98(8):186-188.
369. Pegova A, Abe H, Boldyrev A. Hydrolysis of carnosine and related compounds by mammalian carnosinases. Comp Biochem Physiol B 2000; 127: 443-446.
370. Boldyrev AA, Dupin AM, Bunin AY, Babizhayev MA, Severin SE. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int 1987; 15: 1105-1113.
371. Aldini G, Facino RM, Beretta G, Carini M, Facino MR. Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives. Biofactors 2005; 24(1-4):7-87.
372. Aldini G, Orioli M, Carini M, Maffei FR. Profiling histidine-containing dipeptides in rat tissues by liquid chromatography/ electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004; 39(12): 1417-1428.
373. Orioli M, Aldini G, Beretta G, Facino RM, Carini M. LC-ESI-MS/MS determination of 4-hydroxy-trans-2-nonenal Michael adducts with cysteine and histidine-containing peptides as early markers of oxidative stress in excitable tissues. J Chromatogr B Analyt Technol Biomed Life Sci 200; 827(1):109-118.
374. Reddy VP, Garrett MR, Perry G, Smith MA. Carnosine: A versatile antioxidant and antiglycating agent. Sci Aging Know Environ 2005; 2005(18):12.
375. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007; 581 (5): 1067-1070.
376. Babizhayev MA, Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol 2009; 4(1): 4-37.
377. Babizhayev MA, Micans P, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: A clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther 2009; 16(6):517-533.
378. Babizhayev MA, Burke L, Micans P, Richer SP. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: Glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. Clin Interv Aging 2009; 4(1):31-50.
379. Babizhayev MA. Current ocular drug delivery challenges for N-acetylcarnosine: Novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Pat Drug Deliv Formul 2009; 3(3): 229-65.
380. Babizhayev, M.A., Meguro, K. Combined use of carnosinase inhibitor with l-carnosines and composition. WO2004064866 (2004) and PCTJP2004000351 (2003).
381. Babizhayev, M.A. Aqueous composition, useful to treat eye diseases, comprises N-acetylcarnosine in combination with cellulose compound. US20040192647 (2004).
382. Zhang, W.W. N-acetyl carnosine eye drop used for preventing and treating cataract and its preparing method. CN10998863 (2007).
383. Arnould JM, Frentz R. Presence, isolation and chemical structure of a substance characteristic of cardiac tissue in Carcinus maenas (L.):Beta-alanylhistamine. Comp Biochem Physiol C 1975; 50(1):59-66.
384. Brotman DN, Flancbaum L, Fitzpatrick JC, Fisher H. Presence of carcinine (p-alanylhistamine) in mammalian tissues. FASEB J 1989; 3: 1028.
385. Brotman DN, Flancbaum L, Kang YH, Merrill GF, Fisher H. Positive inotropic effects of carcinine in the isolated, perfused guinea pig heart. Crit Care Med 1990; 18: 317-321.
386. Flancbaum L, Brotman DN, Fitzpatrick JC, Van Es T, Kasziba E, Fisher H. Existence of carcinine, a histamine-related compound, in mammalian tissues. Life Sci 1990; 47: 1587-1593.
387. Ali SM, Tedford CE, Gregory R, Handley MK, Yates SL, Hirth WW, et al. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J Med Chem 1999; 42: 903-909.
388. Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Development of trans-2-[1H-imidazol-4-yl]cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.J Pharmacol Exp Ther 1999; 289: 1160-1168.
389. Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, et al. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289(2): 1151-1159.
390. Tozer MJ, Kalindjian SB. Histamine H3 receptor antagonists. Expert Opin Ther Pat 2000; 10: 1045-1055.
391. Chen Z, Sakurai E, Hu W, Jin C, Kiso Y, Kato M, et al. Pharmacological effects of carcinine on histaminergic neurons in the brain. Br J Pharmacol 2004; 143(5):573-580.
392. Stvolinsky SL, Bulygina ER, Fedorova TN, Meguro K, Sato T, Tyulina OV, et al. Biological activity of novel synthetic derivatives of carnosine. Cell Mol Neurobiol 2010 Apr;30(3):395-404 Epub 2009 Oct 2.
393. Yoshikawa, K., Ishiguro, T. Skin preparation for external use containing phenolic compound in sap of plant of Aceraceae. JP2009067718 (2009).
394. Kawagoe, Y., Akatsuka, M., Ohara, S. Raw material for oral product and oral product using the same. JP2008273923 (2008).
395. Kim, N.W., Lee, Y.S., Choi, B.D., Jeon, H.S. A composition comprising an extract of Ailanthus altissima having antioxidative effect. KR8093663 (2008).
396. Kim, N.W., Lee, Y.S. A cosmetic composition comprising an extract of Vitex rotundifolia l. having antioxidative effect. KR8090745 (2008).
397. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta 1989; 1004: 363-371.
398. Babizhayev MA, Bozzo CE. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim et Biophys Acta 1994; 1225: 326-337.
399. Babizhayev MA. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm 2008; 34(10):107110-89.
400. Miyachi Y, Imamura S, Niwa Y. Decreased skin superoxide dismutase activity by a single exposure of ultraviolet radiation is reduced by liposomal superoxide dismutase pretreatment. J Invest Dermatol 1987; 89: 111-112.
401. Bloemendal H, deJong W, Jaenicke R, Lubsen NC, Slingsby C, Tardieu A. Ageing and vision: Structure, stability and function of lens crystallins. Prog Biophys Mol Biol 2004; 86: 407-485.
402. Horwitz J. Alpha crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 1992; 89: 10449-10453.
403. Spector A. The search for a solution to senile cataracts. Procter Lecture. Invest Ophthalmol Vis Sci 1984; 25:130-145.
404. Nagaraj RH, Sell DR, Prabhakaram M, Ortwerth BJ, Monnier VM. High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. Proc Natl Acad Sci USA 1991; 88(22):10257-10261.
405. Andley UP, Clark BA. Generation of oxidants in the near-UV photooxidation of human lens alpha-crystallin. Invest Ophthalmol Vis Sci 1989; 30(4): 706-713.
406. McDermott M, Chiesa R, Roberts JE, Dillon J. Photooxidation of specific residues in alpha-crystallin polypeptides. Biochemistry 1999; 30(35): 8653-8660.
407. Takemoto L, Boyle D. Increased deamidation of asparagine during human senile cataractogenesis. Mol Vis 2000; 6:164-168.
408. Lorand L. Transglutaminase mediated cross-linking of proteins and cell aging: The erythrocyte and lens models. In: Zappia V, Ed. Advances in Post-Translational Modifications of Proteins and Aging. Plenum Press: New York 1988; 79-94.
409. Srivastava K, Chaves JM, Srivastava OP, Kirk M. Multi-crystallin complexes exist in the water-soluble high molecular weight protein fractions of aging normal and cataractous human lenses. Exp Eye Res 2008; 87(4): 356-366.
410. Babizhayev MA, Kasus-Jacobi A. Imidazole-containing peptide-based compounds in sight-threatening age-related eye diseases. Expert Rev Ophthalmol 2009; 4(6): 581-586.
411. Attanasio F, Cataldo S, Fisichella S, Nicoletti S, Nicoletti VG, Pignataro B, et al. Protective effects of L- and D-carnosine on alpha-crystallin amyloid fibril formation:Implications for cataract disease. Biochemistry 200; 48(27): 6522-6531.
412. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000; 26(3):163-176.
413. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28(5): 419-426.
414. Baynes JW. The role of AGEs in aging: Causation or correlation. Exp Gerontol 2001; 36(9):1527-1537.
415. Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006; 126(2): 291-299.
416. Stitt AW, Curtis TM. Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 2005; 57: 156-168.
417. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, et al. Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3. Diabetes 2005; 54(3):785-794.
418. Hunt JV, Bottoms MA, Mitchinson MJ. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 1993; 291 (2): 529-535.
419. Szwergold BS. Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun 2005; 336(1): 36-41.
420. Babizhayev, M.A., Seguin, M.-C. Coupling product obtained from histamine and an amino acid. US5792784 (1998).
421. Conner JR, Beisswenger PJ, Szwergold BS. Some clues as to the regulation, expression, function, and distribution of fructosamine-3-kinase and fructosamine-3-kinase-related protein. Ann N Y Acad Sci 2005; 1043: 824-836.
422. Guiotto A, Ruzza P, Babizhayev MA, Calderan A. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem 2007; 15(18): 6158-6163.
423. Hipkiss AR. Accumulation of altered proteins and ageing: Causes and effects. Exp Gerontol 2006; 41: 464-473.
424. Schoneich C. Protein modification in aging: An update. Exp Gerontol 2006; 41: 807-813.
425. Hipkiss AR. Error-protein metabolism and ageing. Biogerontology 2009; 10(4):523-529.
426. Babizhayev MA, Deev AI. Free radical oxidation of lipids and thiol groups in the formation of a cataract. Biofizika 1986; 31(1):109-114.
427. Boring CC, Squires TS, Tong T T. Cancer statistics, 1991. SA Cancer J Clinic 1991; 41: 19-36.
428. Calabrese V, Randazzo SD, Morganti PG, Rizza V. An ex vivo biochemical mode to study the antioxidant clinical properties of cosmetic products in human antiaging skin care. Drugs Exp Clin Res 1999; 25(1): 43-49.
429. Spector A, Rothschild C. The effect of calcium upon the reaggregation of bovine alpha crystallin. Invest Ophthalmol 1973; 12(3): 225-231.
430. 2+ enhances the molecular chaperone function and stability of alpha-crystallin. Biochemistry 2008; 47(2): 804-816.
431. 2+ binding, redox silencing, and cytoprotective effects of the small heat shock proteins alphaA- and alphaB-crystallin. J Mol Biol 2008; 382(3):812-824.
432. Calabrese V, Scapagnini G, Catalano C, Bates TE, Geraci D, Pennisi G, et al. Regulation of heat shock protein synthesis in human skin fibroblasts in response to oxidative stress: Role of vitamin E. Int J Tissue React 2001; 23(4):127-135.
433. Kang JH. Protective effects of carnosine and N-acetylcarnosine on salsolinol-mediated Cu, Zn-superoxide dismutase inactivation. Bull Korean Chem Soc 2007; 208(10): 1881-1884.
434. Ukeda H, Hasegawa Y, Harada Y, Sawamura M. Effect of carnosine and related compounds on the inactivation of human Cu,Zn- superoxide dismutase by modification of fructose and glycolaldehyde. Biosci Biotechnol Biochem 2002; 66(1): 36-43.
435. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH, Kang TC. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu, Zn-superoxide dismutase modification. Biochim et Biophys Acta 2002; 1570: 89-96.
436. Babizhayev MA, Deyev AI. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta 1989; 1004(1): 124-133.
437. Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine: Significance of histidine. Life Sci 2004; 75: 1379-1389.
438. Mehta AD, Seidler NW. Beta-alanine suppresses heat inactivation of lactate dehydrogenase. J Enzyme Inhib Med Chem 2005; 20(2):199-203.
439. Yan H, Harding JJ. Carnosine inhibits modifications and decreased molecular chaperone activity of lens alpha-crystallin induced by ribose and fructose 6-phosphate. Mol Vis 2006;12: 205-214.
440. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated alpha-crystallin: An in vitro study. Arch Biochem Biophys 2004; 427: 110-115.
441. Price DI, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Appl Biol Chem 2001; 276: 48967-48972.
442. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 1998; 248(1):28-32.
443. Shi Q, Yan H, Li MY, Harding JJ. Effect of a combination of carnosine and aspirin eye drops on streptozotocin - induced diabetic cataract in rats. Mol Vis 2009;15: 2129-2138.
444. Yamagishi S-I, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005; 1: 93-106.
445. Muranov KO, Dizhevskaia AK, Boldyrev AA, Karpova OE, Sheremet NL, Polunin GS, et al. Search for chaperon-like anticataract drugs, the antiaggregants of lens crystallins. Communication. 1. Chaperon-like activity of N-acetyl carnosine dipeptide: In vitro study on a model of ultraviolet-induced aggregation of beta-L-crystallin. Vestn Talmol 2008; 124(2): 3-6.
446. Hipkiss AR, Brownson C, Bertani MF, Ruiz E, Ferro A. Reaction of carnosine with aged proteins: Another protective process? Ann NY Acad Sci 2002; 959: 285-294.
447. Jonak C, Klosner G, Trautinger F. Heat shock proteins in the skin. Int J Cosmet Sci 2006; 28(4): 233-241.
448. Calabrese V, Cornelius C, Mancuso C, Pennisi G, Calafato S, Bellia F, et al. Cellular stress response: A novel target for chemo-prevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 2008 Jul 16 [Epub ahead of print].
449. Ohkawara T, Nishihira J, Nagashima R, Takeda H, Asaka M. Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: Relevant to cytoprotective heat shock proteins. World J Gastroenterol 2006; 12(38): 6178-6181.
450. Mikami K, Otaka M, Watanabe D, Goto T, Endoh A, Miura K, et al. Zinc L-carnosine protects against mucosal injury in portal hypertensive gastropathy through induction of heat shock protein 72. J Gastroenterol Hepatol 2006; 21(11):1669-1674.
451. Kosmaoglou M, Schwarz N, Bett JS, Cheetham ME. Molecular chaperones and photoreceptor function. Trends Mol Med 2001; 7(9): 414-421.
452. Gavin BA, Arruda SE, Dolph PJ. The role of carcinine in signaling at the Drosophila photoreceptor synapse. PLoS Genet 2007; 3(12): 206.